Opus Genetics Inc Ordinary Shares IRD
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $3.48
- Day Range
- $3.27–3.44
- 52-Week Range
- $1.05–5.80
- Bid/Ask
- $3.26 / $3.27
- Shares Outstanding
- 82.57M
- Market Cap
- $269.58M
- Volume/Avg
- 623,466 / 990,671
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 21.92
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes seven adeno-associated virus (AAV)-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, CNGB1, RDH12, NMNAT1, and MERTK. The company operates in one operating segment, which is the business of developing products related to vision performance and health.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 28
- Website
- https://www.opusgtx.com
Valuation
|
Metric
|
IRD
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 21.92 |
Price/Cash Flow | — |
Price/Earnings
IRD
Financial Strength
|
Metric
|
IRD
|
|---|---|
Quick Ratio | 6.71 |
Current Ratio | 7.13 |
Interest Coverage | — |
Quick Ratio
IRD
Profitability
|
Metric
|
IRD
|
|---|---|
Return on Assets (Normalized) | −77.71% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −1,232.14% |
Return on Assets
IRD
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|&PR!n<X | LOCK|Mrjp | $121B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|<vl%G?B | LOCK|$kFC | $70B | |||
| argenx SE ADR
ARGX
| LOCK|^DTF<@^ | LOCK|dY> | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|#Zr$lv | LOCK|k>R< | $37B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|>XR?KG< | LOCK|>B> | $37B | |||
| Moderna Inc
MRNA
| LOCK|%M?&#ZY | LOCK|vl | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|gQn&R$s | LOCK|@<%#c | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|W^@d@rx | LOCK|tl | $23B | |||
| Incyte Corp
INCY
| LOCK|&k!XQfM | LOCK|>$ | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|tLb>sd^ | LOCK|G> | $16B |
United States